View article

During the last 15 years, attention to the measurement of family spillover effects of illness and their inclusion in costeffectiveness analyses (CEAs) has increased substantially. First, with a focus on direct medical costs borne by the family, followed by attention to the burden of informal caregiving, and most recently, with the consideration of changes in health and quality of life for caregivers and family members [1–6]. Through this broad diversity of studies in this emerging field, the considerable burden of illness that extends to caregivers and family members has been defined and the magnitude of these effects is starting to be quantified. We are delighted to introduce in this themed issue of Pharmocoeconomics on family spillover effects, a set of papers that both presents new applications and addresses methodological questions. Together, these papers highlight emerging work in the field and provide a vibrant …